Ornatinib is another chemotherapeutic agent indicated for hepatocellular carcinoma in phase 3 clinical trials with significant VEGFR-2 inhibition, which features an indolin-2-one ring [17]. The gene discussed is KDR; the disease is hepatocellular carcinoma.